Thrombosis and Haemostasis· 2026Q1
Managing Abnormal Uterine Bleeding During Anticoagulant Therapy in Clinical Practice
- 0citations
- Q1SCImago
- 2026year
Short summary
Women on anticoagulants, including DOACs like rivaroxaban and apixaban, experience a higher incidence of abnormal uterine bleeding (AUB), particularly heavy menstrual bleeding (HMB) exceeding 80 mL per cycle.
AI-generated from the title and abstract; the full text is not read.
Key points
- Anticoagulant use, particularly DOACs, increases the risk of abnormal uterine bleeding (AUB) in women of reproductive age.
- Heavy menstrual bleeding (HMB) is defined as >80 mL blood loss per cycle or significant life disruption.
- Women on anticoagulants report higher incidences of HMB, leading to reduced quality of life and economic costs.
- Management strategies include gynecological consultation, therapy adjustments, tranexamic acid, and iron deficiency treatment.
AI-generated from the title and abstract; the full text is not read.
Abstract
Anticoagulant therapies, including heparins, vitamin K antagonists, and direct oral anticoagulants (DOACs) such as rivaroxaban, apixaban and dabigatran, are crucial for the treatment and the prevention of venous thromboembolism (VTE). While DOACs offer improved safety profiles, their use, espe-cially in women of reproductive age, increases the risk of abnormal uterine bleeding (AUB), partic-ularly heavy menstrual bleeding (HMB). HMB, defined as blood loss exceeding 80 mL per cycle or causing significant life disruption, is associated with reduced quality of life and substantial economic costs. Women on anticoagulants report higher incidences of HMB, often requiring adjustments in therapy or additional interventions. Management strategies include the referral for a gynecological consultation, the adjustment of hormonal therapy and anticoagulant treatment, the administration of tranexamic acid, and the treatment of iron deficiency. The review underscores the importance of a comprehensive, personalized approach to managing AUB in women on anticoagulants to optimize both anticoagulation effectiveness and patient quality of life.
The authors' abstract, as published at the source. Thrombosis and Haemostasis, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Internal Medicine
Internal MedicineMedicine